Last $20.85 USD
Change Today +0.90 / 4.51%
Volume 774.7K
TTPH On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

tetraphase pharmaceuticals i (TTPH) Snapshot

Open
$20.00
Previous Close
$19.95
Day High
$21.19
Day Low
$19.91
52 Week High
10/1/14 - $21.19
52 Week Low
04/15/14 - $8.01
Market Cap
541.1M
Average Volume 10 Days
584.0K
EPS TTM
$-2.22
Shares Outstanding
26.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRAPHASE PHARMACEUTICALS I (TTPH)

tetraphase pharmaceuticals i (TTPH) Related Bloomberg News

View More Bloomberg News

tetraphase pharmaceuticals i (TTPH) Related Businessweek News

No Related Businessweek News Found

tetraphase pharmaceuticals i (TTPH) Details

Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative bacteria. The company is conducting a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to-oral step-down therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and preclinical Gram-negative program for multidrug-resistant Gram-negative infections. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

46 Employees
Last Reported Date: 03/6/14
Founded in 2006

tetraphase pharmaceuticals i (TTPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $394.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $293.8K
Chief Medical Officer
Total Annual Compensation: $338.2K
Senior Vice President of Biology
Total Annual Compensation: $273.0K
Compensation as of Fiscal Year 2013.

tetraphase pharmaceuticals i (TTPH) Key Developments

Tetraphase Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 02:00 PM

Tetraphase Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 02:00 PM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Guy MacDonald, Chief Executive Officer, President and Director.

Tetraphase Pharmaceuticals, Inc. - Special Call

To discuss the top-line data from the lead-in portion of the IGNITE 2 Phase 3 trial

Tetraphase Pharmaceuticals, Inc. Announces Oral Dosing Data from Lead-In of Ignite 2 Phase 3 Trial of Eravacycline in Cuti Support Advancement to Pivotal Portion

Tetraphase Pharmaceuticals, Inc. announced that positive top-line results from the lead-in portion of its IGNITE 2 clinical trial, a two-part Phase 3 clinical trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI), support advancement of the trial into its pivotal portion. Data from the lead-in portion demonstrated that both IV-to-oral dosing regimens of eravacycline (1.5 mg/kg IV followed by 200 mg or 250 mg) compared favorably to levofloxicin. The responder outcome (the primary endpoint for the FDA) for the IV-to-oral 200 mg, IV-to-oral 250 mg and levofloxacin groups were 70.8%, 64.3% and 52.2%, respectively. The microbiological response (the primary endpoint for the European Medicines Agency) were 75.0%, 64.3% and 56.5%, respectively. The pharmacokinetics of both oral doses of eravacycline were comparable to the IV formulation. Overall, treatment was generally well tolerated in all three groups with the most common adverse events reported being nausea and emesis. Only two patients discontinued treatment as a result of drug related adverse events.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTPH:US $20.85 USD +0.90

TTPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TTPH.
View Industry Companies
 

Industry Analysis

TTPH

Industry Average

Valuation TTPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 66.1x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 55.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRAPHASE PHARMACEUTICALS I, please visit www.tphase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.